Navigation Links
Genomic Health Announces Commencement of QUASAR Clinical Validation Study for Oncotype DX(R) Colon Cancer Assay
Date:1/12/2009

- Company to Provide Update on Pipeline Efforts at 27th Annual J.P. Morgan Healthcare Conference -

REDWOOD CITY, Calif., Jan. 12 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX) announced today that it has initiated an independent clinical validation study for its 18-gene Oncotype DX(R) colon cancer assay. Utilizing more than 1,200 patient samples from the landmark QUASAR trial, the validation study will use prospectively defined endpoints to assess the clinical utility of the Oncotype DX colon cancer assay to predict likelihood of recurrence for stage II colon cancer patients treated with surgery alone and the magnitude of treatment benefit with chemotherapy following surgery. Results from the study are expected to be reported in the second half of 2009.

Stage II colon cancer (also known as Dukes' Stage B) affects an approximately 30-40,000 people each year in the United States and the current treatment paradigm is unclear. About a third of patients receive adjuvant chemotherapy, usually 5-fluorouracil/leucovorin (5FU/LV) or combinations that include 5FU/LV; however, research indicates that only 2-4 percent benefit from this treatment, which has significant associated toxicity. While there are existing clinical markers traditionally associated with higher-risk in colon cancer patients, there is no clinically validated genomic test available that predicts the likelihood of recurrence or magnitude of chemotherapy benefit for individual patients.

"There is a critical need for more targeted approaches in treating the tens of thousands of patients with stage II colon cancer and the initiation of this study brings us one step closer to delivering a tool that may do that," said Steven Shak, M.D., chief medical officer, Genomic Health. "Over the past two years we have partnered with the National Surgical
'/>"/>

SOURCE Genomic Health, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Sirius Genomics Announces New Collaboration with UK Critical Care Genomics Group
2. Rosetta Genomics Announces Exclusive Distribution Agreement With Teva Pharmaceutical Industries Ltd.
3. AutoGenomics Invited to Present at the 2009 JPMorgan Healthcare Conference
4. Rosetta Genomics Announces Commercial Availability of Its Third MicroRNA-Based Diagnostic Test: miRview(TM) meso
5. Transgenomic Receives Accreditation From College of American Pathologists
6. Genomic Health Announces Appointment of Ginger Graham to Board of Directors
7. Rosetta Genomics to Webcast Panel Presentation at RBC Capital Markets 2008 Healthcare Conference
8. Genomic Health to Present Multiple New Studies at 31st Annual San Antonio Breast Cancer Symposium
9. Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS
10. Transgenomic Signs Letter of Intent for an Agreement to Exclusive License With Option to Acquire Power3 Medical Products Neurodegenerative Diagnostics
11. Rosetta Genomics Announces Conference Call and Webcast of Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... The US markets on Friday, September 19, ... Jones Industrial Average finished at 17,279.74, up 0.08% and ... S&P 500 finished the session 0.05% lower at 2,010.40. ... finished on a positive note. The S&P 500 Health ... 0.10%, with the index gaining 6.95% in the previous ...
(Date:9/22/2014)... -- Spherix Incorporated (SPEX) -- an intellectual property development company committed ... that the United States Patent & Trademark Office (USPTO) issued ... September that is part of a standard essential family of ... , Application number: US 13/728,867 , Publication date: ... The listed inventors of the new patent, ...
(Date:9/21/2014)... (PRWEB) September 21, 2014 Chemical ... global challenges such as clean air and safe ... and natural products. Chemists, environmentalists, food scientists, educators, ... the research in the field of Chemistry for ... Chemical Sciences is one of the fastest emerging ...
(Date:9/20/2014)... Netherlands (PRWEB) September 20, 2014 ... technologies to perform a groundbreaking surgery at the specialized ... the mare's superficial digital flexor tendon was ruptured 90% ... kind of injury is a death sentence for a ... America stem cell treatments . This revolutionary ...
Breaking Biology Technology:Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 2Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 3Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 4Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 5Spherix Notified by United States Patent & Trademark Office of New Standard Essential Patent Issued to Spherix 2Spherix Notified by United States Patent & Trademark Office of New Standard Essential Patent Issued to Spherix 3Chemistry for Global Development during the Open Access Week 2Chemistry for Global Development during the Open Access Week 3World’s first tendon replacement using Nanofiber and activated MediVet Stem Cell Fraction 2World’s first tendon replacement using Nanofiber and activated MediVet Stem Cell Fraction 3
... , Baltimore Convention Center ... BALTIMORE, Aug. 11 This summit will attract more than 1,200 ... It will feature more than 100 speakers, including governors, federal officials, ... cell policies, scientific breakthroughs, and human-interest stories. This is your ...
... , SAN FRANCISCO, Aug. 11 ... stage biopharmaceutical company developing a proprietary breakthrough class of targeted ... private placement financing with gross proceeds of US $5,123,521, exceeding ... anticipated on or before September 15, 2009, with additional proceeds ...
... 11 /PRNewswire-Asia-FirstCall/ -- American Oriental,Bioengineering, Inc. (NYSE: ... to improving health through the development, manufacture and,commercialization of ... ("OTC"),products in China, announced today that the Audit Committee ... of Ernst & Young Hua Ming ("EY") as,the Company,s ...
Cached Biology Technology:World Stem Cell Summit to Be Held in Baltimore 2Jennerex Closes $5 Million First Tranche of Series C Financing 2
(Date:9/21/2014)... protein therapy that disrupts the process that causes cancer ... through the blood stream and start aggressive new growths ... metastasis, can cause cancer to spread with deadly effect. ... cancer fall prey to metastatic forms of the disease," ... describes a new therapeutic approach in Nature Chemical ...
(Date:9/19/2014)... University of Oklahoma biology professor will study multifunctional ... leg movements with a National Science Foundation grant ... project. , Ari Berkowitz, professor in the Department ... will focus on the differences between the multifunctional ... what neurotransmitters they use and what connections they ...
(Date:9/19/2014)... legume plants regulate their symbiotic relationship with soil ... through the plant structure from leaves into the ... in the roots. This collaborative study was conducted ... Biology, the Graduate University for Advanced Studies (SOKENDAI), ... in Japan. , Legumes, an important plant ...
Breaking Biology News(10 mins):Stanford researchers create 'evolved' protein that may stop cancer from spreading 2Stanford researchers create 'evolved' protein that may stop cancer from spreading 3Stanford researchers create 'evolved' protein that may stop cancer from spreading 4For legume plants, a new route from shoot to root 2
... LA Research led by Lauren Cole, a public ... of Public Health and Director of the Epidemiology Program ... the incidence of head and neck cancer has risen ... with the greatest increase among middle-aged white men. At ...
... gene called XRCC2 cause increased breast cancer risk, according to ... Human Genetics . The study looked at families that have ... in the currently known breast cancer susceptibility genes. Sean ... professor in the Department of Oncological Sciences at the University ...
... such as the Iberian lynx, are under an increasingly serious ... that can even survive in extremely arid environments. A study ... to adapt according to climate. The life cycle of ... patterns of people and goods. These parasites and the pathogens ...
Cached Biology News:LSUHSC research finds HPV-related head & neck cancers rising, highest in middle-aged white men 2A new breast cancer susceptibility gene 2Ticks can adapt to the Spain's climatic diversity 2
... Microarrays designed for genome-wide microRNA expression ... and powerful Paraflo microfluidic on-chip synthesis ... part of our comprehensive microRNA Expression ... The Maize microRNA Microarray contains ...
... LTQ XL extends the legendary MSn performance ... generate structural information through Thermo Scientifics innovations ... LTQ XL is the only mass spectrometer ... and CID. Pulsed Q Collision Induced ...
... is a rugged, compact, lab-quality ... information you need - at ... of gas mixtures is critical, ... generates more data in less ...
... PolarScreen Peroxisome Proliferator-Activated Receptor-gamma (PPARGamma) ... sensitive and efficient method for ... ligands using fluorescence polarization (FP). ... binding domain (PPARGamma-LBD) with an ...
Biology Products: